Mukka Proteins Limited (MUKKA) AI Stock Analysis

1 Followers

Mukka Proteins Limited

(NSE:MUKKA)

Select Model

Rating:59.6Neutral

Price Target:INR 28.00▲(5.34% Upside)

Action:reiterated

Date:09/06/26

The overall score is constrained primarily by financial risks: while Mukka Proteins is growing rapidly and remains profitable, margin pressure, heavy reliance on debt, and persistently negative operating and free cash flows materially weaken its quality profile. Technicals are supportive, with a strong uptrend and positive momentum, but stretched indicators raise near-term volatility and correction risk. Valuation at a mid-teens P/E without a disclosed dividend is neither clearly cheap nor expensive, leaving the risk-reward balance in a cautiously neutral zone.

Positive Factors

Strong Revenue GrowthStrong multi-year revenue expansion, capped by approximately 45% growth in 2026, indicates the company is gaining business and processing more demand. If this momentum persists, higher scale can support operating leverage, strengthen customer reach, and provide a durable foundation for future earnings growth.

Negative Factors

Weak Cash GenerationPersistently negative operating cash flow, including a deeply negative result in 2026, indicates that reported profits are not translating reliably into cash. This weakens earnings quality and can force the company to seek external funding to support working capital, expansion, and ongoing operations.

Mukka Proteins Limited (MUKKA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 7.95B
Dividend Yield: ―
Average Volume (3M): 72.30K
Price to Earnings (P/E): 10.0
Beta (1Y): 0.95
Revenue Growth: 84.77%
EPS Growth: 67.73%
Country: India
Employees: 358
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Mukka Proteins Limited Business Overview & Revenue Model

Company Description

Mukka Proteins Limited, based in Mangaluru, India, operates as a prominent manufacturer and supplier of protein products, extending its reach both domestically and internationally. The company specializes in a variety of fish-derived offerings, inclu...

Mukka Proteins Limited Financial Statement Overview

Summary

Strong revenue and net income growth are offset by recent margin compression, rising leverage, and persistently weak operating and free cash flows, resulting in a mid-range financial strength score.

Income Statement

72Positive

Balance Sheet

63Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	20.43B	14.49B	10.06B	13.80B	11.56B	7.66B
Gross Profit	3.58B	2.23B	2.32B	1.69B	1.34B	799.87M
EBITDA	1.95B	1.45B	948.84M	1.22B	962.04M	550.04M
Net Income	792.36M	520.58M	464.59M	700.52M	440.75M	242.08M
Balance Sheet
Total Assets	18.60B	16.21B	10.76B	9.41B	5.75B	3.92B
Cash, Cash Equivalents and Short-Term Investments	715.34M	604.29M	30.75M	944.38M	265.48M	180.42M
Total Debt	8.50B	7.79B	4.53B	3.65B	2.62B	1.75B
Total Liabilities	13.32B	10.92B	6.20B	5.32B	4.19B	2.97B
Stockholders Equity	5.38B	4.99B	4.41B	3.96B	1.34B	898.23M
Cash Flow
Free Cash Flow	0	-2.97B	-1.36B	-1.68B	-737.46M	-63.29M
Operating Cash Flow	0	-1.59B	-1.12B	-1.50B	-563.28M	48.08M
Investing Cash Flow	0	-1.46B	-349.86M	-475.94M	-33.25M	-122.84M
Financing Cash Flow	0	3.15B	555.53M	2.66B	746.65M	158.58M

Mukka Proteins Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price26.58

Price Trends

50DMA27.22Negative

100DMA25.69Positive

200DMA24.30Positive

Market Momentum

MACD0.02Negative

RSI52.05Neutral

STOCH59.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MUKKA, the sentiment is Positive. The current price of 26.58 is above the 20-day moving average (MA) of 25.92, below the 50-day MA of 27.22, and above the 200-day MA of 24.30, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 59.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MUKKA.

Mukka Proteins Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MUKKA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:HATSUN	75Outperform	INR 236.25B	62.55	―	0.99%	17.90%	9.78%
IN:AVANTIFEED	71Outperform	INR 103.74B	22.07	―	1.34%	8.99%	-27.78%
IN:SKMEGGPROD	70Outperform	INR 12.07B	11.59	―	0.54%	21.31%	89.98%
IN:PARAGMILK	63Neutral	INR 40.87B	32.89	―	0.33%	13.13%	-10.08%
IN:MUKKA	60Neutral	INR 8.05B	10.03	―	―	84.77%	67.73%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:MKPL	47Neutral	INR 1.49B	30.82	―	―	17.76%	-50.16%

* General Sector Average

Performance Comparison

IN:MUKKA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MUKKA	Mukka Proteins Limited	26.58	0.44	1.68%
IN:AVANTIFEED	Avanti Feeds Limited	746.85	-9.23	-1.22%
IN:HATSUN	Hatsun Agro Product Limited	1013.85	-47.31	-4.46%
IN:MKPL	M K Proteins Limited	3.89	-2.62	-40.25%
IN:PARAGMILK	Parag Milk Foods Ltd.	331.10	-18.98	-5.42%
IN:SKMEGGPROD	SKM Egg Products Export (India) Ltd.	230.20	17.06	8.00%

Mukka Proteins Limited Corporate Events

Mukka Proteins Reports Strong Q2 FY27 Growth and Expands Global Market Access

Nov 7, 2026

Mukka Proteins reported consolidated Q2 FY27 revenue of ₹5,088.70 million, up 108.06% year on year, while EBITDA rose 90.73% to ₹501.18 million. Profit after tax increased 157.51% to ₹177.27 million, supported by strong export demand, although quarte...

Mukka Proteins Shareholders Clear All Resolutions at 16th AGM via E-Voting

Sep 12, 2026

Mukka Proteins Limited held its 16th Annual General Meeting on September 10, 2026, via video conference in compliance with the Companies Act and relevant regulatory circulars. The company reported that all resolutions set out in the AGM notice, inclu...

Mukka Proteins Holds 16th AGM via Virtual Platform with Broad Shareholder Participation

Sep 10, 2026

Mukka Proteins Limited held its 16th Annual General Meeting on September 10, 2026 via video conferencing and other audio-visual means, in line with MCA and SEBI circulars. The proceedings were deemed to be conducted at the company’s registered office...

Mukka Proteins Extends Tenure of Independent Directors and Top Executives at AGM

Sep 10, 2026

At its 16th Annual General Meeting on 10 September 2026, Mukka Proteins Limited secured shareholder approval to reappoint three non-executive independent directors for second five-year terms commencing in January 2027. The move reinforces board conti...

Mukka Proteins Wins EU Certification for Eco Sphere Organic Fertilizer

Sep 4, 2026

Mukka Proteins Limited has received an EU – Inputs Attestation from ECOCERT S.A.S., France, confirming that its Eco Sphere Organic Fertilizer is suitable for use in organic farming under specific EU programme conditions. The certification, issued in...

Mukka Proteins Sets Fully Virtual 16th AGM for 10 September

Aug 19, 2026

Mukka Proteins Limited has announced that its 16th Annual General Meeting will be held on 10 September 2026 at 3:00 p.m. IST through video conferencing and other audio-visual means, in line with regulatory provisions allowing virtual shareholder meet...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Mukka Proteins Limited AI Stock Analysis